TY - JOUR
T1 - Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®)
AU - Poynard, Thierry
AU - Vergniol, Julien
AU - Ngo, Yen
AU - Foucher, Juliette
AU - Munteanu, Mona
AU - Merrouche, Wassil
AU - Colombo, Massimo
AU - Thibault, Vincent
AU - Schiff, Eugene
AU - Brass, Clifford A.
AU - Albrecht, Janice K.
AU - Rudler, Marika
AU - Deckmyn, Olivier
AU - Lebray, Pascal
AU - Thabut, Dominique
AU - Ratziu, Vlad
AU - De Ledinghen, Victor
PY - 2014
Y1 - 2014
N2 - Background & Aims FibroTest™ (FT) and Transient Elastography (TE) have been validated as non-invasive markers of METAVIR fibrosis stages from F0 to F4 using biopsy, and as prognostic markers of liver related mortality in patients with chronic hepatitis C. The aim was to extend the validation of FT and TE as markers of critical steps defined by occurrence of cirrhosis without complications (F4.1), esophageal varices (F4.2), and severe complications (F4.3): primary liver cancer, variceal bleeding, or decompensation (ascites, encephalopathy, or jaundice). Methods The updated individual data of 3927 patients (1046 cirrhotics) without complications at baseline were pooled from three prospective cohorts called "EPIC", "Paris", and "Bordeaux" cohorts. Results At 5 years, among 501 patients without varices at baseline (F4.1) varices occurred in 19 patients [F4.2 incidence of 4.0% (95% CI 2.2-5.8)]. The predictive performance (AUROC) of FT was 0.77 (0.66-0.84; p
AB - Background & Aims FibroTest™ (FT) and Transient Elastography (TE) have been validated as non-invasive markers of METAVIR fibrosis stages from F0 to F4 using biopsy, and as prognostic markers of liver related mortality in patients with chronic hepatitis C. The aim was to extend the validation of FT and TE as markers of critical steps defined by occurrence of cirrhosis without complications (F4.1), esophageal varices (F4.2), and severe complications (F4.3): primary liver cancer, variceal bleeding, or decompensation (ascites, encephalopathy, or jaundice). Methods The updated individual data of 3927 patients (1046 cirrhotics) without complications at baseline were pooled from three prospective cohorts called "EPIC", "Paris", and "Bordeaux" cohorts. Results At 5 years, among 501 patients without varices at baseline (F4.1) varices occurred in 19 patients [F4.2 incidence of 4.0% (95% CI 2.2-5.8)]. The predictive performance (AUROC) of FT was 0.77 (0.66-0.84; p
KW - Cirrhosis complications
KW - Elastography
KW - Fibrosis stages
KW - FibroTest™
KW - Hepatocellular carcinoma
KW - Prognostic factors
KW - Surrogate markers
UR - http://www.scopus.com/inward/record.url?scp=84896392780&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84896392780&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2013.11.016
DO - 10.1016/j.jhep.2013.11.016
M3 - Article
C2 - 24291240
AN - SCOPUS:84896392780
VL - 60
SP - 706
EP - 714
JO - Journal of Hepatology
JF - Journal of Hepatology
SN - 0168-8278
IS - 4
ER -